Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track TEVA with free AI briefings, catalyst countdowns, and dilution alerts.

TEVA · TEVA PHARMACEUTICAL INDUSTRIES LTD

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$3.7B Cash on Hand

CF+ Cash Runway

Follow TEVA by email Get an email when TEVA pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about TEVA, unsubscribe in one click. Privacy

🧪 Trial & FDA Catalysts

Jan 2023 · Phase 1 · Results Expected · A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV
Registry primary completion date, not a results date
Dec 2020 · Phase 3 · Results Expected · Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthrit
Registry primary completion date, not a results date
Jan 2020 · Phase 2 · Results Expected · Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With P
Registry primary completion date, not a results date
Jan 2020 · Phase 1 · Results Expected · To Assess the Patients' Ability to Self-Administer Fasinumab
Registry primary completion date, not a results date
Dec 2019 · Phase 3 · Results Expected · Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonste
Registry primary completion date, not a results date
Sep 2019 · Phase 3 · Results Expected · A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Napr
Registry primary completion date, not a results date

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
Omacetaxine FDA approved Oct 2012 · Synribo (discontinued)	Myelodysplastic Syndromes	Phase 1/2 · NCT02835794	Withdrawn
Fasinumab	Osteoarthritis of the Knee or Hip	Phase 3 · NCT02683239	Completed
Laquinimod	Relapsing Remitting Multiple Sclerosis	Phase 2 · NCT00745615	Terminated
Hydroxychloroquine	COVID-19	Phase 2 · NCT04358068	Terminated
Diclofenac	Osteoarthritis, Knee	Phase 2 · NCT03949673	Terminated
TV-1106	Growth Hormone-Deficiency	Phase 2 · NCT02092077	Terminated
Anti-CD20 Monoclonal Antibody TL011	Rheumatoid Arthritis	Phase 1 · NCT01123070	Completed
Fasinumab PFS	Osteoarthritis, Knee	Phase 1 · NCT03491904	Completed
MabThera infusions	Rheumatoid Arthritis	Phase 1 · NCT01123070	Completed
Fluvoxamine	Healthy Volunteers	Phase 1 · NCT05532358	Completed
Fasinumab AI	Osteoarthritis, Knee	Phase 1 · NCT03491904	Completed

Also used in these trials (approved or third-party drugs, not TEVA's own candidates): Armodafinil, Naproxen, Filgrastim, Somatropin, Decitabine, Cytarabine, Celecoxib, Azithromycin, Azacitidine, Caffeine.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

TEVA holds $3.7B in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TEVA files for a raise →

Get the full TEVA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TEVA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z